Vancouver, Canada – January 8, 2020:  Contextual Genomics, a leading cancer genomics company, announced that it has named Brady Davis to its executive team. Mr. Davis, a veteran of the life sciences, healthcare and software industries, joins as Senior Vice President, Business Development of the Company, responsible for global strategy and business development.

Mr. Davis has more than 25 years of leadership experience in the life sciences, healthcare and software fields. Previous roles have included Vice President, market development and strategy at DNAnexus, head of strategy and market development for Illumina focused on informatics, and the head of healthcare strategy and business development at Oracle. Mr. Davis currently serves on the Board of Directors and Advisory Board of multiple non-profit organizations, including the Global Alzheimer’s Association Interactive Network, Cancer Informatics for Cancer Centers (Ci4CC), Muscular Dystrophy Association, and the University of Washington Center for Commercialization. Mr. Davis is a graduate of the University of Washington.

“Cancer genomic testing has tremendous potential, and there is a dire need to make it affordable and accessible. Contextual Genomics is democratizing cancer genomic testing through a decentralized model bringing highly accurate and cost-effective personalized cancer testing to patients and providers at the local level,” said Mr. Davis.

“Brady is truly a world-class leader in the healthcare industry. He has deep experience with many of our customers and a keen understanding of the current challenges and trends of the global clinical genomics market. We are excited to have Brady on our leadership team,” Michael Ball, Contextual Genomics’ Chief Executive Officer, commented in a statement.

About Contextual Genomics (www.canexiahealth.com):

Contextual Genomics develops cost-effective and clinically actionable molecular tests that guide diagnosis and treatment of cancer. These customized tests are offered by our partner laboratories around the world with Contextual Genomics conducting cloud-based bioinformatics services via a SaaS model.  The collection of data via this robust network of partners and the use of machine-learning tools allows Contextual Genomics to improve patient care through improved clinical trial enrollment and new treatment algorithms. Contextual Genomics is founded and managed by global leaders in cancer medicine and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.

About Contextual Genomics’ Products:

Contextual Genomics has developed the  FIND IT®and FOLLOW IT® cancer panels. Both panels are multiplex, next-generation sequencing genomic assays designed for rapid deployment into labs around the world. Both FIND IT and FOLLOW IT evaluate the mutation status of tumour DNA (FIND IT for solid tumours; FOLLOW IT for cell-free circulating tumour DNA in plasma) at 146 well-characterized positions, identifying the somatic mutations that have the greatest potential to impact treatment decisions. QUALITY NEXUS® is a quality control system embedded into all FIND IT and FOLLOW IT assays and into Contextual Genomics’ cloud-based analysis engine.  FIND IT and FOLLOW IT physician reports provide clear information on test interpretation and linkages to current therapeutic options.

###

Contacts:

Contextual Genomics Media Contact

Email: media@canexiahealth.com

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.

Back

Recent Resources

Blog

March 2, 2021

Assessing the Real World Accuracy of ctDNA Diagnostics

Canexia Health's Chief Scientific Officer writes about the importance of combining different approaches to obtain correct results for ctDNA diagnostics. While high sensitivity is important, it must be contextualized with other key measurements.

Blog

February 17, 2021

How 3 organizations are tackling disparities in cancer care

Before COVID-19 lockdowns halted travel, I attended a community cancer conference in Washington D.C. last year. I had an interesting conversation with a community practice leader, Jessica, about how socioeconomic factors have a big impact on clinical outcomes. In the last few months, I have been researching value-based care innovations in cancer care. I was encouraged to find multiple examples of value-based care initiatives that also focus on reducing disparities. How are they approaching challenges of inequity in cancer care? Here are three initiatives with innovative approaches.

In the News

February 4, 2021

Pilot of new cancer test in Canada shows promise as faster alternative to conventional biopsies

The COVID-19 pandemic has delayed thousands of surgical procedures across the country, including tissue biopsies needed for cancer diagnosis. But it’s also pushing demand for alternatives that allow patients to be tested for signs of tumours without even needing to enter a hospital. As part of a new pilot called Project ACTT, more than 800 Canadian cancer patients have been tested through liquid biopsies, which involve taking a blood sample and looking for signs of tumour DNA. That federally funded project, a partnership led by Vancouver-based Canexia Health, offers the potential for a more efficient alternative for cancer testing that can save hospital resources and lower the risk of infection.